[go: up one dir, main page]

MA33178B1 - Pipéridines substituées comme antagonistes de ccr3 - Google Patents

Pipéridines substituées comme antagonistes de ccr3

Info

Publication number
MA33178B1
MA33178B1 MA34225A MA34225A MA33178B1 MA 33178 B1 MA33178 B1 MA 33178B1 MA 34225 A MA34225 A MA 34225A MA 34225 A MA34225 A MA 34225A MA 33178 B1 MA33178 B1 MA 33178B1
Authority
MA
Morocco
Prior art keywords
ccr3 antagonists
present
piperidines substituted
pharmaceutically acceptable
relates
Prior art date
Application number
MA34225A
Other languages
English (en)
Inventor
Marc Grundl
Horst Dollinger
Riccardo Giovannini
Christoph Hoenke
Matthias Hoffmann
Jan Kriegl
Domnic Martyres
Georg Rast
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Majdoubi Siham Tarik Groupe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Majdoubi Siham Tarik Groupe filed Critical Boehringer Ingelheim Int
Publication of MA33178B1 publication Critical patent/MA33178B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS SUBSTITUÉS DE FORMULE 1, DANS LAQUELLE A, R1, R2, R3 ET R4 SONT TELS QUE DÉFINIS DANS LA DESCRIPTION. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES ANTAGONISTES DE CCR3, PLUS PARTICULIÈREMENT DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT UN VECTEUR PHARMACEUTIQUEMENT ACCEPTABLE ET UNE QUANTITÉ THÉRAPEUTIQUEMENT EFFICACE D'AU MOINS L'UN DES COMPOSÉS DE LA PRÉSENTE INVENTION OU DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE.
MA34225A 2009-04-08 2010-04-01 Pipéridines substituées comme antagonistes de ccr3 MA33178B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09157653 2009-04-08
EP09174917 2009-11-03
PCT/EP2010/054396 WO2010115836A1 (fr) 2009-04-08 2010-04-01 Pipéridines substituées comme antagonistes de ccr3

Publications (1)

Publication Number Publication Date
MA33178B1 true MA33178B1 (fr) 2012-04-02

Family

ID=42561233

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34225A MA33178B1 (fr) 2009-04-08 2010-04-01 Pipéridines substituées comme antagonistes de ccr3

Country Status (30)

Country Link
US (3) US8278302B2 (fr)
EP (1) EP2417120B1 (fr)
JP (1) JP5466246B2 (fr)
KR (1) KR101690979B1 (fr)
CN (1) CN102388032B (fr)
AP (1) AP2989A (fr)
AR (1) AR076228A1 (fr)
AU (1) AU2010233849B2 (fr)
BR (2) BRPI1013821B1 (fr)
CA (1) CA2753151C (fr)
CL (1) CL2011002197A1 (fr)
CO (1) CO6501183A2 (fr)
DK (1) DK2417120T3 (fr)
EA (1) EA021072B1 (fr)
EC (1) ECSP11011427A (fr)
ES (1) ES2613696T3 (fr)
GE (1) GEP20135863B (fr)
HU (1) HUE030787T2 (fr)
IL (1) IL214309A (fr)
MA (1) MA33178B1 (fr)
MX (1) MX2011010584A (fr)
MY (1) MY161903A (fr)
NZ (1) NZ594597A (fr)
PE (1) PE20120135A1 (fr)
PL (1) PL2417120T3 (fr)
PT (1) PT2417120T (fr)
SG (2) SG10201401347QA (fr)
TW (1) TWI466880B (fr)
UY (1) UY32547A (fr)
WO (1) WO2010115836A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013079696A1 (fr) * 2011-12-01 2013-06-06 Glaxo Group Limited Procédés de traitement et de prévention de maladies oculaires
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
CN104619707A (zh) 2012-07-31 2015-05-13 协和发酵麒麟株式会社 稠环杂环化合物
JP6382816B2 (ja) * 2013-07-24 2018-08-29 田辺三菱製薬株式会社 眼科疾患治療剤
CN106573915B (zh) * 2014-08-01 2020-12-25 纽韦卢森公司 针对布罗莫结构域有活性的化合物
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
EP3721916B1 (fr) * 2016-03-31 2023-09-27 National Center for Geriatrics and Gerontology Matériau de prétraitement dentaire et trousse de régénération de tissu dentaire
EP3606525B1 (fr) * 2017-04-05 2025-12-10 Alkahest, Inc. Compositions destinées à traiter des troubles associés au vieillissement à l'aide d'inhibiteurs de ccr3
AU2018248425B2 (en) * 2017-04-05 2024-03-28 Alkahest Inc. Methods and compositions for treating retina-associated disease using CCR3-inhibitors
US20200054622A1 (en) * 2017-04-05 2020-02-20 Alkahest, Inc. Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
CN110869017B (zh) 2017-05-12 2023-05-05 英安塔制药有限公司 细胞凋亡信号调节激酶1抑制剂及其使用方法
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN107602457A (zh) * 2017-10-10 2018-01-19 重庆奥舍生物化工有限公司 一锅法合成6‑甲基‑2‑氨基‑异烟酸的方法
CN111343983A (zh) * 2017-10-13 2020-06-26 万能溶剂有限公司 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
IL278368B2 (en) 2018-05-02 2024-06-01 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2019213239A1 (fr) 2018-05-02 2019-11-07 Enanta Pharmaceuticals Inc. Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation
SG11202010115RA (en) 2018-05-15 2020-11-27 Alkahest Inc Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
SG11202102105VA (en) * 2018-09-26 2021-04-29 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
WO2020106707A1 (fr) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7907121L (sv) * 1979-08-27 1981-02-28 Astra Laekemedel Ab Ftalimidinderivat
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
CA2318088A1 (fr) 1998-01-21 1999-07-29 Yoshisuke Nakasato Antagonistes du recepteur de la chemokine et procedes d'emploi desdits antagonistes
CA2319781A1 (fr) * 1998-02-02 1999-08-05 Liping Wang Amines cycliques utilisees en tant que modulateurs de l'activite du recepteur de chemokine
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
DE10233366A1 (de) 2002-07-23 2004-02-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
WO2005040129A2 (fr) 2003-10-24 2005-05-06 F. Hoffmann-La Roche Ag Antagonistes du recepteur ccr3
US7705153B2 (en) * 2004-02-05 2010-04-27 Schering Corporation Bipiperdine derivatives useful as CCR3 antagonists
WO2005095339A1 (fr) 2004-03-31 2005-10-13 Pfizer Products Inc. Dicyanopyrrolidines inhibiteurs de la dipeptidyl peptidase iv
AU2005243535A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Novel substituted thiophenecarboxamides, their production and their use as medicaments
CN101048418A (zh) 2004-10-07 2007-10-03 贝林格尔·英格海姆国际有限公司 Pi3－激酶
JP2006137718A (ja) * 2004-11-12 2006-06-01 Astellas Pharma Inc インドール若しくはインダゾール誘導体
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
JP3701964B1 (ja) 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
EP1877376A1 (fr) 2005-04-28 2008-01-16 Boehringer Ingelheim International GmbH Nouveaux composes destines au traitement de maladies inflammatoires
WO2006118256A1 (fr) 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. Dérivés de 2-aminoquinazoline
JP2009533416A (ja) 2006-04-12 2009-09-17 ファイザー・リミテッド ケモカインｃｃｒ５受容体の調節剤としてのピロリジン誘導体
GB0701992D0 (en) 2007-02-02 2007-03-14 7Tm Pharma As Grehlin Receptor Modulators
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
US8008092B2 (en) 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW201000446A (en) 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists

Also Published As

Publication number Publication date
US20100261687A1 (en) 2010-10-14
SG175079A1 (en) 2011-11-28
KR101690979B1 (ko) 2016-12-29
TWI466880B (zh) 2015-01-01
CN102388032B (zh) 2015-01-14
CA2753151A1 (fr) 2010-10-14
US8278302B2 (en) 2012-10-02
BRPI1013821A8 (pt) 2019-09-17
US8653075B2 (en) 2014-02-18
SG10201401347QA (en) 2014-05-29
KR20120034590A (ko) 2012-04-12
NZ594597A (en) 2014-02-28
BR122019017002B1 (pt) 2021-08-10
AU2010233849A1 (en) 2011-08-18
IL214309A0 (en) 2011-09-27
ES2613696T3 (es) 2017-05-25
AP2011005817A0 (en) 2011-08-31
UY32547A (es) 2010-11-30
WO2010115836A4 (fr) 2010-12-09
PL2417120T3 (pl) 2017-04-28
HK1164295A1 (en) 2012-09-21
CL2011002197A1 (es) 2012-03-23
PT2417120T (pt) 2017-02-03
BRPI1013821A2 (pt) 2016-04-05
EA021072B1 (ru) 2015-03-31
BRPI1013821B1 (pt) 2020-03-31
AR076228A1 (es) 2011-05-26
DK2417120T3 (en) 2016-12-19
ECSP11011427A (es) 2011-11-30
WO2010115836A1 (fr) 2010-10-14
CN102388032A (zh) 2012-03-21
AP2989A (en) 2014-09-30
AU2010233849B2 (en) 2014-05-08
JP5466246B2 (ja) 2014-04-09
GEP20135863B (en) 2013-06-25
EP2417120B1 (fr) 2016-10-26
CO6501183A2 (es) 2012-08-15
TW201103901A (en) 2011-02-01
MY161903A (en) 2017-05-15
EA201101398A1 (ru) 2012-04-30
JP2012514024A (ja) 2012-06-21
CA2753151C (fr) 2017-02-28
EP2417120A1 (fr) 2012-02-15
PE20120135A1 (es) 2012-02-29
HUE030787T2 (en) 2017-06-28
MX2011010584A (es) 2011-10-19
USRE45323E1 (en) 2015-01-06
IL214309A (en) 2014-02-27
US20130023517A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA54229B1 (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA31766B1 (fr) Composés organiques
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA30421B1 (fr) Pyrrolidinones substituees par un piperidinyle en tant qu'inhibiteurs de la 11-bêta-hydroxysteroïde deshydrogenase 1
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA30476B1 (fr) Derives de type cyclohexylpyrazole-lactame comme inhibiteurs de la 11-beta-hydroxysteroïde deshydrogenase de type 1
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
HRP20090235A2 (hr) Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub>
MA34767B1 (fr) Compositions et procédés pour la modulation de fxr
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
MA31000B1 (fr) Derives 2-aza-bicyclo[3.1.0]hexane
MA35184B1 (fr) Antagonistes de trpv4
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
GB0510143D0 (en) Novel compounds A1
TN2010000130A1 (fr) Derives de quinazolinedione, leur preparation et leurs applications therapeutiques
MA32170B1 (fr) Nouveaux derives d'aminomethylbenzene
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA30703B1 (fr) Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii.